Key facts
- Axcynsis Therapeutics’s last known valuation is $36.1M.
- It has raised $21.0M; the latest was Early Stage VC ($6.0M) in Oct 2024.
- Notable investors include Hapi Investment Management, TIBS - Trinity funds.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Axcynsis Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Axcynsis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axcynsis Therapeutics
Developer of antibody-drug conjugate therapies designed for treating cancer. The company's platform leverages proprietary technologies to create antibody-toxin conjugates, enabling healthcare companies to target the delivery of cytotoxic payloads to cancer cells while minimizing side effects on healthy tissues.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2022
- Employees
- 24
- Website
- axcynsis.com/
- Ownership
- Privately Held (backing)
Axcynsis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axcynsis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axcynsis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.